FAQ/Help |
Calendar |
Search |
Today's Posts |
06-18-2013, 06:31 PM | #1 | ||
|
|||
Member
|
Adamas Pharmaceuticals, Inc. presented final results today from a Phase 2/3 clinical trial of ADS-5102 (amantadine HCl extended release) capsules demonstrating a statistically significant improvement in levodopa-induced dyskinesia (LID) as measured by change from baseline at week 8 versus placebo in the Unified Dyskinesia Rating Scale (UDysRS). ADS-5102 is Adamas' investigational extended-release formulation of amantadine intended for once-nightly administration that is being studied for the treatment of LID in Parkinson’s disease (PD) patients.
http://bit.ly/11N09Fl |
||
Reply With Quote |
"Thanks for this!" says: | Stand Tall (06-19-2013) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
EASED™ (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dys | Parkinson's Disease | |||
Positive Results With Extended-Release Carbidopa-Levodopa | Parkinson's Disease | |||
IPX066 versus immediate-release (IR) carbidopa-levodopa (CD-LD), Phase III results | Parkinson's Disease | |||
Ceregene announces positive phase 1 results ... | Parkinson's Disease | |||
Positive Results of Phase 3 Study of Fampridine-SR on walking | Multiple Sclerosis |